Organization
SpringWorks Therapeutics
7 clinical trials
5 abstracts
12 posters
Clinical trial
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant MorbidityStatus: Active (not recruiting), Estimated PCD: 2023-09-20
Clinical trial
A Phase 1/2a Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Mirdametinib in Combination With BGB-3245 in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2026-10-31
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)Status: Active (not recruiting), Estimated PCD: 2022-04-07
Clinical trial
A Phase 2 Trial of Nirogacestat in Patients With Recurrent Ovarian Granulosa Cell TumorsStatus: Active (not recruiting), Estimated PCD: 2026-07-01
Abstract
Monitoring ovarian function in oncology studies: Results and insights from the DeFi phase 3 study of nirogacestat in desmoid tumor.Org: Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, University of Washington and Fred Hutchinson Cancer Research Centre, University of Michigan, Rogel Comprehensive Cancer Center,
Clinical trial
A Phase 1a/1b Dose Escalation, Dose Expansion Study of SW-682 in Participants With Advanced Solid Tumors Enriched for Those With Hippo Pathway MutationsStatus: Not yet recruiting, Estimated PCD: 2030-01-01
Abstract
Tumor volume and T2 hyperintensity changes from DeFi: A phase 3, randomized, controlled trial of nirogacestat in patients with desmoid tumors.Org: Medpace Inc, PharPoint Research, SpringWorks Therapeutics,
Abstract
Population pharmacokinetic-pharmacodynamic model of nirogacestat effects on B-cell maturation antigen in healthy subjects.Org: SpringWorks Therapeutics, SpringWorksTherapeutics, ICON BioAnalytical Laboratories, Nuventra Pharma Sciences,
Abstract
Impact of nirogacestat on pain, a key symptom in patients with desmoid tumors (DT): Results from the phase 3 DeFi study.Org: IQVIA Inc., Bratislava, Slovakia, IQVIA, Amsterdam, Netherlands, SpringWorks Therapeutics, Universität Heidelberg, Mannheim Cancer Center (MCC),
Abstract
A basket-platform trial for neurofibromatosis type 1: A potential model for rare cancer predisposition syndromes.Org: Novartis Pharmaceuticals, German HIT-LOGGIC-Registry for LGG in children and adolescents, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, SpringWorks Therapeutics, AstraZeneca,